Avid Bioservices Inc (CDMO)

[hutschi]

Technavio has published a new report on the global liquid biopsy market from

2017-2021.


Srinivas Sashidhar, a lead research analyst from Technavio, specializing in research on in-vitro diagnostics (http://www.technavio.com/industries/vitro-diagnostics?utm_source=T2&utm_medium=BW&utm_campaign=Media) sector, says, “To treat diseases like lung cancer and breast cancer at an early stage, liquid biopsies are performed, as they help in the detection of cancer. An increasing number of cancer cases will increase the need for liquid biopsy in the market. Skilled lab technicians are required to handle liquid biopsy systems such as polymerase chain reactions and assays.”


The global liquid biopsy market
(http://www.technavio.com/report/global-vitro-diagnostics-global-liquid-biopsy-market-2017-2021?utm_source=T2&utm_medium=BW&utm_campaign=Media) is expected to grow at a staggering CAGR of more than 20% in next few years. A liquid biopsy is a novel technology in the cancer diagnostic market, which has attracted many investors in the market. New entrants and small companies in the market such as GRAIL, Guardant Health, Inivata, and Pathway Genomics have received funding from various investors such as OrbiMed Advisors, Imperial Innovations, and IBM Watson Founders Fund. It helped these companies with multi-center clinical trials, product development, and enabled them to commercialize the products.


Request a sample report: https://goo.gl/ulnDDq (https://goo.gl/ulnDDq)